However, their efficacy is observed in only a small subset of patients.[39] The responses to PD-L1 inhibitor treatments are influenced by several factors, such as CD8 T-effector cell phenotype, high neoantigen, and tumor mutation burden. The gene discussed is CD8A; the disease is neoplasm.